Evaluation of Rectal Dose During High-Dose-Rate Intracavitary Brachytherapy for Cervical Carcinoma

Sha, Rajib Lochan; Reddy, Palreddy Yadagiri; Rao, Ramakrishna U.; Muralidhar, KR; Kudchadker, Rajat J.

doi:10.1016/j.meddos.2010.09.006

Cited by 5 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sha et al [13] measured the rectum dose delivered in intracavitary application with 0.1 cm 3 ionization chamber probe and compared with ICRU reference point dose calculated by TPS. Their results for the 86 patients evaluated prospectively showed that the difference between the measured and TPS calculated dose was less than 5%, 5-10% and 10-14% in 52, 26 and 8 patients.…”

Section: Discussionmentioning

confidence: 99%

Rectal and Bladder Dose Measurements in the Intracavitary Applications of Cervical Cancer Treatment with HDR Afterloading System: Comparison of TPS Data with MOSFET Detector

et al. 2019

View full text Add to dashboard Cite

Background: Intracavitary brachytherapy plays a major role in management of cervical carcinoma. Assessment of dose received by OAR’s therefore becomes crucial for the estimation of radiation toxicities in high dose rate brachytherapy.Objective: The purpose of this study is to evaluate the role of in vivo dosimetry in HDR brachytherapy and to compare the actual doses delivered to OAR’s with those calculated during treatment planning.Materials and Methods: A total of 50 patients were treated with Microselectron HDR. Out of 50 patients, 26 were treated with a dose of 7 Gy and 24 with a dose of 9 Gy, prescribed to point A. Brachytherapy planning and evaluation of dose to the bladder and rectum was done on TPS & in vivo dosimetry was performed using portable MOSFET.Results: The calibration factors calculated for both the dosimeters are almost equal and are 0.984 cGy/mV and 1.0895 cGy/mV. For bladder, dose deviation was found to be within +/- 5% in 28 patients, +/- 5-10% in 14 patients, +/- 10-15% in 4 patients. The deviation between the TPS-calculated dose and the dose measured by MOSFET for rectum was within +/- 5% in 31 patients, +/- 5–10% in 8 patients, and +/- 10–15% in 7 patients.Conclusion: TPS calculated doses were slightly higher than that measured by MOSFET. The use of a small size of MOSFET dosimeter is an efficient method for accurately measuring doses in high-dose gradient fields typically seen in brachytherapy. Therefore, to reduce risk of large errors in the dose delivery, in vivo dosimetry can be done in addition to TPS computations.

show abstract

Section: Discussionmentioning

confidence: 99%

Rectal and Bladder Dose Measurements in the Intracavitary Applications of Cervical Cancer Treatment with HDR Afterloading System: Comparison of TPS Data with MOSFET Detector

et al. 2019

View full text Add to dashboard Cite

show abstract

“…They can be used also to evaluate dose to the rectum during gynecological treatments (Sha et al, 2011;Wang et al, 2010;Lambert et al, 2007;Waldh€ ausl et al, 2005;Sakata et al, 2002;Deshpande et al, 1997). An in vivo dosimetric method of interest is alanine/Electron Spin Resonance (ESR) dosimetry (De Angelis et al, 1999;Kuntz et al, 1996;Schaeken and Scalliet, 1996), that has been used in different clinical practices (Baffa and Kinoshita, 2014;Wagner et al, 2008;Schultka et al, 2006;Ciesielski et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Measurement of rectum dose by in vivo alanine/ESR dosimetry in gynecological 192Ir HDR brachytherapy

Bravo-Miranda

Rech

Oliveira

et al. 2015

Radiation Measurements

View full text Add to dashboard Cite

“…There are several systems to perform IVD of the rectum (8,9). However, various research groups reported inconsistencies regarding the calculated dose and values gathered from IVD (9,10). Dislocation of the applicator during patients movements, streak artifacts caused by the applicators during computed tomography (CT) or the time span between planning and treatment are possible explanations for these differences (9,11).…”

Section: Introductionmentioning

confidence: 99%

Einfluss der Rektum- und Blasenfüllung sowie der Applikatorposition auf die Rektumdosis bei der vaginalen Brachytherapie des Endometriumkarzinoms. Ein Vergleich der in vivo gemessenen und mittels Planungssystem kalkulierten Dosis.

Luise¹

View full text Add to dashboard Cite

PURPOSE: The impact of rectal filling and bladder volume on in vivo rectal dosimetry (IVD) in vaginal cuff brachytherapy (VCBT) is unknown. The purpose of this study was to compare rectal doses from IVD with those calculated from treatment planning and to identify influencing factors. MATERIALS AND METHODS: We collected data of 80 VCBT sessions, four for each of 20 patients. Each was retrospectively compared with doses determined by the treatment planning system. Factors potentially predicting the IVD rectum dose were analyzed. RESULTS: For a series of 80 brachytherapy applications, the calculated mean dose to the rectum was 2.52 Gy. The mean difference between all calculated and measured doses for the 80 applications with five probe positions each was 0.09 Gy ( p 5 0.952) proving high overall accordance between IVD and calculated doses at the rectum. The mean volume of the rectum was 119 AE 57 cm 3 . The rectal volume was not statistically significantly associated with the IVD or the calculated rectum doses. At the third and fourth rectal probe position in craniocaudal ordering, increased filling of the urinary bladder resulted in decreased measured and calculated doses ( p ! 0.05 for both). A rectum pointing position of the applicator significantly increased the maximum rectum dose compared with a bladder-oriented position ( p ! 0.05). CONCLUSIONS: IVD provided valuable data for rectal exposure in VCBT. Increased bladder filling and vaginal applicator positioning off the rectum elicited related with less rectal radiation exposure, whereas rectal filling did not. Further confirmation including assessment of IVD in bladder is pending to define optimal dosimetric conditions in VCBT.

show abstract

Evaluation of Rectal Dose During High-Dose-Rate Intracavitary Brachytherapy for Cervical Carcinoma

Cited by 5 publications

References 10 publications

Rectal and Bladder Dose Measurements in the Intracavitary Applications of Cervical Cancer Treatment with HDR Afterloading System: Comparison of TPS Data with MOSFET Detector

Rectal and Bladder Dose Measurements in the Intracavitary Applications of Cervical Cancer Treatment with HDR Afterloading System: Comparison of TPS Data with MOSFET Detector

Measurement of rectum dose by in vivo alanine/ESR dosimetry in gynecological 192Ir HDR brachytherapy

Einfluss der Rektum- und Blasenfüllung sowie der Applikatorposition auf die Rektumdosis bei der vaginalen Brachytherapie des Endometriumkarzinoms. Ein Vergleich der in vivo gemessenen und mittels Planungssystem kalkulierten Dosis.

Contact Info

Product

Resources

About